Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -252.79% is 24% above its 5-year average of -331.13%, near the high end of its 5-year range (-5076.86%–565.32%).
15.39% above its 12-month average of -298.78%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -440.23%.
EBITDA MARGIN
-252.79%
EBITDA MARGIN AVG TTM
-298.78%
EBITDA MARGIN AVG 3Y
-335.94%
EBITDA MARGIN AVG 5Y
-331.13%
EBITDA MARGIN AVG 10Y
-327.18%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+15.39%
CURRENT VS 3Y AVG
+24.75%
CURRENT VS 5Y AVG
+23.66%
CURRENT VS 10Y AVG
+22.74%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Profound Medical Corp.
Market Cap
$220.93M
EBITDA Margin
-252.79%
TTM Avg
-298.78%
3Y Avg
-335.94%
5Y Avg
-331.13%
Market Cap
$218.30M
EBITDA Margin
29.55%
TTM Avg
-2937.39%
3Y Avg
-39292.92%
5Y Avg
-29539.33%
Market Cap
$216.91M
EBITDA Margin
-847.24%
TTM Avg
-1408.92%
3Y Avg
-1408.92%
5Y Avg
-1408.92%
Market Cap
$225.24M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$215.07M
EBITDA Margin
66.70%
TTM Avg
45.54%
3Y Avg
40.95%
5Y Avg
43.86%
Market Cap
$227.60M
EBITDA Margin
-25.05%
TTM Avg
-32.88%
3Y Avg
-63.97%
5Y Avg
-61.52%
Market Cap
$214.24M
EBITDA Margin
12.17%
TTM Avg
10.71%
3Y Avg
-1.62%
5Y Avg
-12.53%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $220.93M | -252.79% | -298.78% | -335.94% | -331.13% |
| Keros Therapeutics, Inc. (KROS)vs › | $218.30M | 29.55% | -2937.39% | -39292.92% | -29539.33% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $216.91M | -847.24% | -1408.92% | -1408.92% | -1408.92% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $225.24M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $215.07M | 66.70% | 45.54% | 40.95% | 43.86% |
| Sionna Therapeutics, Inc. (SION)vs › | $214.46M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $227.60M | -25.05% | -32.88% | -63.97% | -61.52% |
| Niagen Bioscience Inc (NAGE)vs › | $214.24M | 12.17% | 10.71% | -1.62% | -12.53% |
| Vogenx Inc. (VOGX)vs › | $227.91M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $210.98M | -533986.11% | -544963.54% | -316138.98% | -211520.31% |
Gross Margin
71.8%
EBITDA Margin
-252.8%
Operating Margin
-256.3%
Net Margin
-171.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -440.23% |
| 2026-03-31 | -148.42% |
| 2025-12-31 | -121.47% |
| 2025-09-30 | -165.74% |
| 2025-06-30 | -618.05% |
| 2025-03-31 | -419.80% |
| 2024-12-31 | -186.51% |
| 2024-09-30 | -361.42% |
| 2024-06-30 | -340.71% |
| 2024-03-31 | -530.02% |
| 2023-12-31 | -2401.20% |
| 2023-09-30 | -363.02% |
| 2023-06-30 | 419.04% |
| 2023-03-31 | -355.81% |
| 2022-12-31 | -4397.14% |
| 2022-09-30 | 420.15% |
| 2022-06-30 | -359.56% |
| 2022-03-31 | 565.32% |
| 2021-12-31 | -5076.86% |
| 2021-09-30 | 315.73% |
| 2021-06-30 | -225.09% |
| 2021-03-31 | 972.71% |
| 2020-12-31 | -1135.20% |
| 2020-09-30 | -211.89% |
| 2020-06-30 | -347.56% |
| 2020-03-31 | -387.41% |
| 2019-12-31 | 215.15% |
| 2019-09-30 | -816.89% |
| 2019-06-30 | -884.31% |
| 2019-03-31 | -149.51% |
| 2018-12-31 | -223.40% |
| 2018-09-30 | -1528.79% |
| 2018-06-30 | -2435.10% |
| 2018-03-31 | -1115.77% |
| 2017-12-31 | -191.02% |
| 2017-09-30 | -312.84% |
| 2017-06-30 | -457.95% |
| 2017-03-31 | -643.07% |
